Clinical Trials Browser

INDUSTRY × aflutinib × Clear all

NCT05364073 2026-03-13

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07185997 2026-02-10

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Phase 3 Recruiting

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms

NCT04858958 2025-11-19

FAVOUR

Phase 1 Active not recruiting

NSCLC

NCT05466149 2025-11-19

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

Phase 2 Active not recruiting

NSCLC

NCT07229599 2025-11-17

A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer

Phase 1/2 Recruiting

Advanced Lung Cancer

NCT05607550 2025-06-22

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05994131 2025-04-30

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Phase 1/2 Recruiting

NSCLC

NCT03787992 2025-04-11

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Phase 3 Active not recruiting

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

NCT02973763 2025-04-03

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

Phase 1 Terminated

NSCLC

NCT03127449 2025-04-03

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Phase NA Terminated

Advanced NSCLC

NCT03452592 2025-04-03

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Phase 2 Terminated

Advanced NSCLC Patients With T790M

NCT04958967 2025-03-14

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

Phase 1 Withdrawn

NSCLC

NCT06868732 2025-03-11

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

Phase 1 Not yet recruiting

Advanced Non-small Cell Lung Cancer